Optimistic Investors Push Guanhao Biotech Co.,Ltd. (SZSE:300238) Shares Up 28% But Growth Is Lacking
Sep 02
Have your own idea? Try our Stock Screener
Markets has moved to Discover
You can now access Markets by navigating to Discover and selecting Markets.
Chinese (SSE) Biotech Industry Analysis
UpdatedSep 03, 2024
DataAggregated Company Financials
Companies73
- 7D0.4%
- 3M-14.7%
- 1Y-24.5%
- YTD-30.7%
Over the last 7 days, the Biotech industry has remained flat, although notably Dizal (Jiangsu) Pharmaceutical gained 5.4%. As for the longer term, the industry has declined 24% in the last year. Earnings are forecast to grow by 39% annually.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 03 Sep 2024 | CN¥769.4b | CN¥154.0b | CN¥14.4b | 30.1x | 53.4x | 5x |
| Thu, 01 Aug 2024 | CN¥835.6b | CN¥161.2b | CN¥17.3b | 31.2x | 48.3x | 5.2x |
| Sat, 29 Jun 2024 | CN¥828.1b | CN¥161.1b | CN¥17.3b | 31.6x | 47.9x | 5.1x |
| Mon, 27 May 2024 | CN¥907.0b | CN¥161.1b | CN¥17.3b | 37x | 52.5x | 5.6x |
| Wed, 24 Apr 2024 | CN¥909.5b | CN¥161.5b | CN¥20.5b | 35.6x | 44.4x | 5.6x |
| Fri, 22 Mar 2024 | CN¥1.0t | CN¥165.5b | CN¥22.0b | 38x | 46.2x | 6.1x |
| Sun, 18 Feb 2024 | CN¥955.7b | CN¥167.9b | CN¥21.4b | 31.9x | 44.6x | 5.7x |
| Tue, 16 Jan 2024 | CN¥1.0t | CN¥167.9b | CN¥21.4b | 38x | 48.7x | 6.2x |
| Thu, 14 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.2x | 52.1x | 6.7x |
| Sat, 11 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.3x | 51.7x | 6.6x |
| Mon, 09 Oct 2023 | CN¥1.1t | CN¥170.9b | CN¥25.2b | 42.6x | 41.7x | 6.2x |
| Wed, 06 Sep 2023 | CN¥1.0t | CN¥170.7b | CN¥25.2b | 38.6x | 40.5x | 6x |
| Fri, 04 Aug 2023 | CN¥1.1t | CN¥174.4b | CN¥28.4b | 39.9x | 38.3x | 6.2x |
| Sun, 02 Jul 2023 | CN¥1.1t | CN¥177.4b | CN¥29.3b | 40.1x | 36.8x | 6.1x |
| Tue, 30 May 2023 | CN¥1.1t | CN¥177.4b | CN¥29.5b | 43.8x | 38.6x | 6.4x |
| Thu, 27 Apr 2023 | CN¥1.2t | CN¥184.2b | CN¥35.1b | 38.8x | 33.3x | 6.4x |
| Sat, 25 Mar 2023 | CN¥1.2t | CN¥185.5b | CN¥36.8b | 41.9x | 33.6x | 6.7x |
| Mon, 20 Feb 2023 | CN¥1.3t | CN¥179.6b | CN¥37.9b | 41.9x | 34.1x | 7.2x |
| Wed, 18 Jan 2023 | CN¥1.3t | CN¥179.3b | CN¥38.3b | 41.8x | 35x | 7.5x |
| Fri, 16 Dec 2022 | CN¥1.3t | CN¥175.6b | CN¥37.9b | 39.5x | 33x | 7.1x |
| Sun, 13 Nov 2022 | CN¥1.2t | CN¥175.8b | CN¥38.0b | 39.2x | 32.6x | 7.1x |
| Tue, 11 Oct 2022 | CN¥1.1t | CN¥174.3b | CN¥40.2b | 29.6x | 27.3x | 6.3x |
| Thu, 08 Sep 2022 | CN¥1.2t | CN¥183.4b | CN¥40.0b | 33.9x | 30.6x | 6.7x |
| Sat, 06 Aug 2022 | CN¥1.3t | CN¥171.2b | CN¥43.3b | 35.4x | 29.4x | 7.4x |
| Mon, 04 Jul 2022 | CN¥1.3t | CN¥168.1b | CN¥42.4b | 40.3x | 31.8x | 8x |
| Wed, 01 Jun 2022 | CN¥1.2t | CN¥168.1b | CN¥42.4b | 35.7x | 28.3x | 7.1x |
| Fri, 29 Apr 2022 | CN¥1.2t | CN¥166.5b | CN¥43.3b | 33.7x | 26.9x | 7x |
| Sun, 27 Mar 2022 | CN¥1.5t | CN¥154.7b | CN¥41.4b | 44.7x | 35.4x | 9.5x |
| Tue, 22 Feb 2022 | CN¥1.4t | CN¥149.8b | CN¥40.2b | 44.3x | 35.4x | 9.5x |
| Thu, 20 Jan 2022 | CN¥1.5t | CN¥143.3b | CN¥39.3b | 49.8x | 38.2x | 10.5x |
| Sat, 18 Dec 2021 | CN¥1.6t | CN¥141.8b | CN¥39.1b | 48.3x | 40x | 11x |
| Mon, 15 Nov 2021 | CN¥1.5t | CN¥145.0b | CN¥40.2b | 47x | 37.4x | 10.4x |
| Wed, 13 Oct 2021 | CN¥1.6t | CN¥132.2b | CN¥34.6b | 46.7x | 44.8x | 11.7x |
| Fri, 10 Sep 2021 | CN¥1.6t | CN¥130.3b | CN¥33.4b | 46.6x | 46.8x | 12x |
Price to Earnings Ratio
46.8x
Current Industry PE
- Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 53.4x which is higher than its 3-year average PE of 39.2x.
- The 3-year average PS ratio of 7.3x is higher than the industry's current PS ratio of 5.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 24% per year over the last three years.
- Meanwhile revenues for these companies have grown 5.7% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -0.56% | |
| Healthcare | 0.67% | |
| Biotech | 0.39% | |
| Biotech | 0.39% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688192 Dizal (Jiangsu) Pharmaceutical | CN¥37.54 | 5.4% +CN¥802.2m | 16.4% | PS90.4x | |
| 600645 Vcanbio Cell & Gene Engineering | CN¥17.13 | 8.7% +CN¥632.6m | -2.0% | PE72.6x | |
| 688443 Chongqing Genrix Biopharmaceutical | CN¥28.19 | 6.0% +CN¥583.0m | -1.5% | PS9471.4x | |
| 300238 Guanhao BiotechLtd | CN¥10.50 | 22.0% +CN¥501.1m | -21.1% | PE136.4x | |
| 688062 Mabwell (Shanghai) Bioscience | CN¥22.54 | 4.9% +CN¥419.6m | 7.8% | PS47.1x |
